Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IQWiG Pans Gilead’s Stribild For HIV On Missing Data, Safety Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s reimbursement watchdog IQWiG has panned Gilead’s HIV combination drug Stribild, saying it is inferior to existing therapies.

You may also be interested in...



It’s Not Just Dosing: Stribild’s Side Effect Profile Could Give It An Edge In HIV Market

Gilead has priced its new 4-in-1 HIV treatment, more commonly referred to as Quad, slightly above the only other integrase inhibitor-based regimen on the market, Merck’s Isentress, but at a 35% premium to its own three-drug combo product, Atripla.

The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild

With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel